Goldman Sachs
VTGN icon

Goldman Sachs’s VistaGen Therapeutics VTGN Stock Holding History

Goldman Sachs’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60,152
Closed -$214K – 6847
2025
Q3 		$214K Buy
+60,152
New +$180K ﹤0.01% 5928
2025
Q1 		– Sell
-194,533
Closed -$574K – 6419
2024
Q4 		$574K Buy
194,533
+18,272
+10% +$51.4K ﹤0.01% 5169
2024
Q3 		$531K Buy
176,261
+1,279
+0.7% +$4.36K ﹤0.01% 5018
2024
Q2 		$609K Buy
174,982
+8,818
+5% +$38.2K ﹤0.01% 4721
2024
Q1 		$877K Buy
166,164
+2,376
+1% +$11.4K ﹤0.01% 4429
2023
Q4 		$842K Buy
+163,788
New +$620K ﹤0.01% 4478
2023
Q3 		– Sell
-57,316
Closed -$107K – 5880
2023
Q2 		$107K Buy
57,316
+54,060
+1,660% +$189K ﹤0.01% 5346
2023
Q1 		$12.2K Sell
3,256
-499
-13% -$2.62K ﹤0.01% 5719
2022
Q4 		$11.6K Sell
3,755
-1,073
-22% -$4.04K ﹤0.01% 5741
2022
Q3 		$22K Sell
4,828
-17,825
-79% -$177K ﹤0.01% 5918
2022
Q2 		$598K Buy
22,653
+794
+4% +$28K ﹤0.01% 4958
2022
Q1 		$813K Sell
21,859
-17,856
-45% -$778K ﹤0.01% 4992
2021
Q4 		$2.32M Sell
39,715
-14,427
-27% -$939K ﹤0.01% 4131
2021
Q3 		$4.45M Buy
54,142
+34,645
+178% +$3.01M ﹤0.01% 3456
2021
Q2 		$1.84M Buy
19,497
+11,887
+156% +$881K ﹤0.01% 4289
2021
Q1 		$486K Buy
7,610
+4,804
+171% +$321K ﹤0.01% 5144
2020
Q4 		$163K Sell
2,806
-1,906
-40% -$48.6K ﹤0.01% 5161
2020
Q3 		$99K Buy
+4,712
New +$97.5K ﹤0.01% 5094
2016
Q4 		– Sell
-406
Closed -$51K – 7111
2016
Q3 		$51K Buy
+406
New +$44.1K ﹤0.01% 6463

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs's VTGN Position: Q4 2025 in Review

Goldman Sachs sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 60,152 shares — an estimated $214K sold.

Goldman Sachs first reported a position in VTGN in Q3 2016 and held it in 19 quarters. The position peaked at $4.45M in Q3 2021. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Goldman Sachs reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Goldman Sachs sold 60,152 VistaGen Therapeutics shares in Q4 2025, an estimated $214K.
  • Goldman Sachs first reported a position in VistaGen Therapeutics in Q3 2016 and held it in 19 quarters.
  • Goldman Sachs's VistaGen Therapeutics position peaked at $4.45M in Q3 2021.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.